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Abstract: The maleimide motif is widely used for the selective chemical modiﬁcation of cysteine residues
in proteins. Despite widespread utilization, there are some potential limitations, including the irreversible
nature of the reaction and, hence, the modiﬁcation and the number of attachment positions. We conceived
of a new class of maleimide which would address some of these limitations and provide new opportunities
for protein modiﬁcation. We report herein the use of mono- and dibromomaleimides for reversible cysteine
modiﬁcation and illustrate this on the SH2 domain of the Grb2 adaptor protein (L111C). After initial
modiﬁcation of a protein with a bromo- or dibromomaleimide, it is possible to add an equivalent of a second
thiol to give further bioconjugation, demonstrating that bromomaleimides offer opportunities for up to three
points of attachment. The resultant protein-maleimide products can be cleaved to regenerate the unmodiﬁed
protein by addition of a phosphine or a large excess of a thiol. Furthermore, dibromomaleimide can insert
into a disulﬁde bond, forming a maleimide bridge, and this is illustrated on the peptide hormone somatostatin.
Fluorescein-labeled dibromomaleimide is synthesized and inserted into the disulﬁde to construct a ﬂuorescent
somatostatin analogue. These results highlight the signiﬁcant potential for this new class of reagents in
protein modiﬁcation.
Introduction
The selective chemical modiﬁcation of cysteine residues in
proteins is widely employed to enable a range of fundamental
biological and biophysical studies.
1,2 Cysteine is often the most
nucleophilic residue in a protein and as such is generally the
easiest to manipulate with chemical reagents in a selective
manner. Furthermore, the relatively low natural abundance
3 of
cysteine makes the introduction of single cysteines via site-
directed mutagenesis and subsequent chemical modiﬁcation a
very effective method to access modiﬁed proteins. A variety of
electrophilic reagents have been developed in order to take
advantage of the nucleophilic characteristics of cysteine, but of
these the maleimide motif remains one of the most widely
employed and there are numerous N-functionalized maleimide
reagents available.
4 The reaction of a cysteine residue with a
maleimide is a highly selective process
5,6 and is considered to
be irreversible.
7,8
Despite the successful utilization of maleimide as a reagent
for the chemical modiﬁcation of proteins, there are limitations.
The irreversible nature of the addition prevents any possibility
for controlled disassembly of the conjugate regenerating the
unmodiﬁed protein, which may be desirable for in vitro or in
vivo applications.
9 Furthermore, there are only two points of
attachment, thus limiting the number of chemical or biological
entities that can be attached to a system of interest. We report
herein on a new class of maleimides, the bromomaleimides,
which offer reversible protein modiﬁcation, three points of
attachment for efﬁcient construction of bioconjugates, and the
ability to insert into disulﬁde bonds, retaining their bridging
character.
Results and Discussion
In prior work we had found that bromomaleimides could be
used for the reversible chemical modiﬁcation of a model system
of the amino acid cysteine.
10 In order to illustrate the applica-
bility of this approach on proteins, we chose to examine a single
point mutant (L111C) of the SH2 domain of the Grb2 adaptor
protein 1, a protein domain which does not otherwise contain
any cysteine residues. We initially treated 1 with Ellman’s
reagent and observed clean formation of the expected mixed
disulﬁde by LCMS, conﬁrming the presence of an available
cysteine residue. Treatment of 1 with 1 equiv of N-methylbro-
momaleimide at 0 °C (sodium phosphate buffer, pH 8) for 1 h
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LCMS. Addition of Ellman’s reagent to 2 led to no reaction,
revealing that the bromomaleimide had reacted exclusively on
the cysteine residue. It should be noted that there are eight lysine
residues present on this protein, and thus, in this case the reagent
is highly selective for thiols over amine nucleophiles. Treatment
of the adduct 2 with 100 equiv of TCEP [tris(2-carboxyethyl)-
phosphine] resulted in 85% conversion back to protein 1,
demonstrating the potential of bromomaleimides for the revers-
ible covalent modiﬁcation of cysteine residues in proteins.
Further experiments demonstrated that the protein-maleimide
adduct 2 could undergo a second thiol conjugate addition. Thus,
treatment of 2 with glutathione (1 equiv) led to the protein-pep-
tide conjugate 3 in 95% conversion (Scheme 1). In a similar
fashion, treatment of 2 with 2-mercaptoethanol (1 equiv) gave
the analogous bis-thioether adduct.
We are proposing that the product 3 is the vicinal and not
geminal bis-thioether by analogy with a related experiment
carried out on the single amino acid model system N-Boc-Cys-
OMe. The addition of an excess of N-Boc-Cys-OMe to
bromomaleimide in the buffer (sodium phosphate buffer, pH
8) afforded the vicinal bis-adduct as a mixture of diastereomers
(Scheme 2), as conﬁrmed by NMR spectroscopy.
We have found that dibromomaleimide can also be employed
for protein modiﬁcation at cysteine. Thus, treatment of the Grb2
SH2 domain 1 with dibromomaleimide led to exclusive forma-
tion of the monobromo adduct 4. Treatment of this adduct with
Ellman’s reagent resulted in no reaction, conﬁrming once again
that the maleimide had added exclusively to the cysteine residue.
Addition of 1 equiv of a second nucleophilic thiol, in the form
of either glutathione or thioglucose, gave the protein-peptide
and protein-sugar conjugates 5 and 6, respectively (Scheme
3). We envisaged that the maleimide-substituted adducts would
still be susceptible to further conjugate addition with nucleo-
philes resulting in cleavage. However, in this instance we found
that TCEP was unsuitable, leading to only a small amount of
cleavage and other unidentiﬁable products. Instead, we found
that treatment of these adducts with an excess of a thiol (2-
mercaptethanol or glutathione, 100 equiv) led to clean conver-
sion to the free unmodiﬁed protein 1.
We are proposing that the mechanism involved in the
cleavage reactions is a conjugate addition-elimination sequence.
In order to provide evidence for our assumption that the
analogous conjugate addition using maleimide is irreversible,
we prepared the succinimide 7 by treatment of 1 with N-
Scheme 1. Modiﬁcation of the Grb2 SH2 Domain (L111C) with N-Methylbromomaleimide
Scheme 2. Conjugate Addition of Cysteine to Bromomaleimide
Generates the Vicinal Bis-cysteine Adduct
Scheme 3. Reversible Modiﬁcation of the Grb2 SH2 Domain (L111C) 1 with Dibromomaleimide
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Protein Modiﬁcation Using Bromomaleimides ARTICLESethylmaleimide (NEM). Treatment of 7 with 100 equiv of TCEP
or mercaptoethanol led to no reaction, even at 37 °Cf o r4h ,
conﬁrming that NEM irreversibly labels the cysteine residue
(Scheme 4).
To gain an appreciation for the relative reactivity of bromo-
maleimides with cysteines, we decided to compare the reaction
times of protein 1 with some commonly employed protein-
modifying reagents. Thus, we treated protein 1 with N-
methylbromomaleimide, dibromomaleimide, N-ethylmaleimide,
and iodoacetamide, respectively, and monitored the reaction
between 5 and 30 min using LCMS (Figure 1). We found that
the order of reactivity was N-methylbromomaleimide ≈ N-
ethylmaleimide>dibromomaleimide.iodoacetamide.Iodoacet-
amide is not shown in Figure 1, as <5% reaction had taken place
after 30 min. The bromomaleimides thus react with the cysteine
residue on a similar time scale to NEM, which is notably far
faster than that of iodoacetamide.
The observed cleavage of the maleimide conjugates by thiols
using excess glutathione suggested the enticing possibility that
thiomaleimides could be used to develop conjugates designed
to cleave in the cytoplasm of cells.
9 To test this hypothesis, we
subjected the protein-sugar conjugate 6 to conditions that would
approximate the conditions of the cytoplasm (20 mM HEPES,
100 mM KCl, 1 mM MgCl2, 1 mM EDTA, pH 7.4, 1 mM
glutathione,
11 37 °C). We observed after 4 h complete cleavage
to afford the protein 1 (Scheme 5). This result suggests that
such conjugates will cleave in cells and offers many exciting
possibilities which we will be actively pursuing in due course.
We have also investigated the utilization of dibromomale-
imides for the modiﬁcation of disulﬁdes. Recent work by
Brocchini and co-workers has highlighted the potential of
modifying disulﬁdes via bridging reagents that retain the
structure and function of the protein.
12-14 We envisaged that
dibromomaleimide could serve as an alternative reagent for the
selective modiﬁcation of disulﬁdes without the requirement for
introduction of an additional asymmetric carbon and with the
resulting adduct incorporating a two-carbon bridge between the
two cysteine residues.
The endogenous peptide hormone somatostatin served as an
excellent system to test our hypothesis. It is a 14-amino acid
peptide containing a disulﬁde bridge, and stable analogues of
somatostatin are clinically employed in the treatment of condi-
tions including acromegaly and gastroenteropancreatic tumors.
15,16
Treatment of somatostatin at pH 6.2 with 1 equiv of TCEP
followed by 1.1 equiv of dibromomaleimide led to complete
conversion to the bridged somatostatin 8 (Scheme 6). This
reaction, together with the conditions used for the Grb2 SH2
domain (pH ) 8), demonstrate the broad pH suitability of these
reagents. Treatment of the maleimide bridged peptide 8 with
2-mercaptoethanol led to complete reversion to afford the
reduced somatostatin 9 after 1 h at room temperature. This
demonstrated that dibromomaleimides offer the ﬁrst effective
reagent for controlled reversible bridging of disulﬁdes.
Fluorescein-5-maleimide is a commercially available reagent
used widely in protein labeling.
4 To demonstrate that bromo-
maleimides provide three possible points of attachment for
protein bioconjugation, we synthesized the ﬂuorescein-di
bromomaleimide 10. The synthesis was carried out by treatment
of dibromomaleic anhydride
17 with ﬂuoresceinamine at room
temperature, followed by heating at reﬂux in AcOH to effect
cyclization to give the maleimide. We chose to treat somatostatin
with this reagent to illustrate the ﬂuorescent labeling of disulﬁde-
containing biomolecules. Thus, treatment of somatostatin with
N-ﬂuoresceindibromomaleimide 10 afforded the ﬂuorescent
bridged construct 11 in quantitative conversion after 10 min.
In order to demonstrate the reversible nature of this modiﬁcation,
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Figure 1. Relative reactivity of Grb2 SH2 domain (L111C) 1 with
N-methylbromomaleimide, dibromomaleimide, and N-ethylmaleimide.
Scheme 5. Cleavage of Grb2 SH2 Domain-Thioglucose
Conjugate 6 under Intracellular-like Conditions
Scheme 4. Irreversible Modiﬁcation of the Grb2 SH2 Domain (L111C) 1 with NEM
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which led after1ht ocomplete cleavage of the ﬂuorescent
maleimide to regenerate the reduced somatostatin (Scheme 7).
The ﬂuorescent properties of ﬂuoresceindibromomaleimide
10 and somatostatin conjugate 11 were conﬁrmed (Figure 2).
Fluoresceinamine is known to be a poor ﬂuorophore until
conjugated (e.g., to a maleimide)
18 and this was observed.
Summary and Implications
In summary, we have shown that mono- and dibromomale-
imides can be used for the selective modiﬁcation of a cysteine
residue in a protein and that the modiﬁcation can be reversed.
Thus, bromomaleimides can be employed in temporary cysteine
modiﬁcation.
19 In addition to the potential beneﬁts afforded by
this temporary or reversible modiﬁcation, these reagents also
provide opportunities for further attachment of functional groups.
Thus, a second thiol can also be added to the protein-maleimide
adducts to form maleimide or succinimide conjugates. As with
other maleimide based reagents,
4 a functional moiety can also
be attached to the nitrogen, thus offering three points of
attachment for protein bioconjugation and we have illustrated
this by synthesizing a ﬂuorescently labeled somatostatin. We
envisage numerous potential applications for bromomaleimides
incorporating functional groups, including biotin or solid
supports for protein puriﬁcation and immobilization; ﬂuoro-
phores, radiolabels, and quantum dots for imaging; polymers,
e.g., PEG, for protein stability and others. In the present work,
we have also shown that the dithiomaleimide constructs cleave
under conditions which approximate those encountered in the
cytoplasm, and this introduces the possibility that these male-
imide reagents could serve as a new motif for the design of
prodrugs. We will report on further developments with this
powerful new class of reagent, in due course.
Experimental Section
Lyophilized somatostatin, 3,4-dibromomaleimide, and ﬂuores-
ceinamine isomer 1 were purchased from Sigma-Aldrich and used
without further puriﬁcation. Bromomaleimide and N-methylbro-
momaleimide were synthesized as described previously.
10 LCMS
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112, 2608–2612.
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0913965.0 (reversible covalent linkage of functional moities), 0913967.6
(functionalization of solid substrates), and 0914321.5 (thiol protecting
group), August 2009.
Scheme 6. Reversible Modiﬁcation of the Disulﬁde Bond of Somatostatin by Dibromomaleimide
Scheme 7. Reversible Modiﬁcation of the Disulﬁde Bond of Somatostatin by a Fluorescent Dibromomaleimide Reagent
Figure 2. Fluorescence measurements of samples excited at 488 nm.
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connected to Waters Acquity Single Quad Detector (SQD) [column,
Acquity uPLC BEH C18 1.7 µm 2.1 × 50 mm; wavelength, 254
nm; mobile phase, 95:5 water (0.1% formic acid):MeCN (0.1%
formic acid), gradient over 4 min to 5:95 water (0.1% formic acid):
MeCN (0.1% formic acid); ﬂow rate, 0.6 mL/min; MS mode, ES+;
scan range, m/z ) 85-2000; scan time, 0.25 s]. Data were obtained
in continuum mode. The electrospray source of the MS was operated
with a capillary voltage of 3.5 kV and a cone voltage of 50 V.
Nitrogen was used as the nebulizer and desolvation gas at a total
ﬂow of 600 L/h. Total mass spectra for protein samples were
reconstructed from the ion series using the MaxEnt 1 algorithm
preinstalled on MassLynx software.
Modiﬁcation of Grb2-SH2 (L111C) 1 with Ellman’s Reagent.
To a solution of Grb2-SH2 (L111C) 1 (100 µL, [protein] 2.0 mg/
mL, 100 mM sodium phosphate, 150 mM NaCl, pH 8.0) at 0 °C
was added Ellman’s reagent (5 µL, 282 mM solution in H2O) at 0
°C. The mixture was vortexed for 1 s and maintained at 0 °C for
10 min, after which the mixture was analyzed by LCMS. Analysis
showed a single product with a mass of 14 370, corresponding to
the mixed disulﬁde, conﬁrming that C111 was available for
functionalization.
Modiﬁcation of Grb2-SH2 (L111C) 1 with N-Methylbromoma-
leimide. To a solution of Grb2-SH2 (L111C) 1 (100 µL, [protein]
2.0 mg/mL, 100 mM sodium phosphate, 150 mM NaCl, pH 8.0) at
0 °C was added N-methylbromomaleimide (5 µL, 2.82 mM solution
in DMF). The mixture was vortexed for 1 s and then maintained at
0 °C for 1 h. Analysis using LCMS showed that the conjugate 2
had been formed in quantitative conversion (mass 14 280). Identical
solutions of 2 formed in this manner were then subjected to the
following experiments.
Ellman’s Test. The solution of 2 was treated with Ellman’s
reagent (5 µL, 282 mM solution in H2O) at 0 °C. The mixture was
vortexed for 1 s and maintained at 0 °C for 10 min, after which
the mixture was analyzed by LCMS. Analysis showed that no
reaction with Ellman’s reagent was evident, highlighting that
N-methylbromomaleimide functionalization had occurred at C111.
TCEP-Mediated Cleavage of 2 To Regenerate Protein 1. The
solution of 2 was treated with TCEP·HCl (5 µL, 282 mM solution
in H2O) at 0 °C. The mixture was vortexed for 1 s and maintained
at 0 °C for 3 h after which the mixture was analyzed by LCMS.
Analysis showed that the protein-N-methylbromomaleimide adduct
2 had been cleaved, yielding Grb2-SH2 (L111C) 1 (mass ) 14 170)
in 85% conversion.
Formation of the Protein-Glutathione Bioconjugate 3. The
solution of 2 was treated with glutathione (5 µL, 2.82 mM solution
in H2O) at 0 °C. The mixture was vortexed for 1 s and maintained
at 0 °C for 2 h, after which the mixture was analyzed by LCMS.
Analysis showed that diconjugate 3 had been formed (mass )
14 588) in 95% conversion. The remaining material was Grb2-SH2
(L111C) 1.
Formation of the Protein-Mercaptoethanol Bioconjugate.
The solution of 2 was treated with 2-mercaptoethanol (5 µL, 2.82
mM solution in H2O) at 0 °C. The mixture was vortexed for 1 s
and maintained at 0 °C for 2 h, after which the mixture was analyzed
by LCMS. Analysis showed that the Grb2-SH2 domain L111C-N-
methylbromomaleimide-2-mercaptoethanol adduct (mass ) 14359)
had been formed in 90% conversion. The remaining material was
Grb2-SH2 domain L111C.
Modiﬁcation of Grb2-SH2 (L111C) 1 with Dibromomaleim-
ide. To a solution of Grb2-SH2 (L111C) 1 (100 µL, [protein] 2.0
mg/mL, 100 mM sodium phosphate, 150 mM NaCl, pH 8.0) at 0
°C was added dibromomaleimide (5 µL, 2.82 mM solution in
DMF). The mixture was vortexed for 1 s then maintained at 0 °C
for 2 h. Analysis using LCMS showed that conjugate 4 had been
formed in quantitative conversion (mass 14346). Identical solutions
of 4 formed in this manner were then subjected to the following
experiments.
Ellman’s Test. The solution of 4 was treated with Ellman’s
reagent (5 µL, 282 mM solution in H2O) at 0 °C. The mixture was
vortexed for 1 s and maintained at 0 °C for 10 min, after which
the mixture was analyzed by LCMS. Analysis showed that no
reaction with Ellman’s reagent was evident, highlighting that
dibromomaleimide functionalization had occurred at C111.
Mercaptoethanol- or Glutathione-Mediated Cleavage of 4
To Regenerate Protein 1. The solution of 4 was treated with
2-mercaptoethanol or glutathione (5 µL, 282 mM solution in H2O)
at 0 °C. The mixture was vortexed for 1 s and maintained at 0 °C
for 4 h, after which the mixture was analyzed by LCMS. Analysis
showed that the protein-dibromomaleimide adduct had been
cleanly cleaved, yielding the Grb2-SH2 (L111C) 1 (mass ) 14170)
in quantitative conversion.
Formation of the Protein-Glutathione Bioconjugate 5. The
solution of 4 was treated with glutathione (5 µL, 2.82 mM solution
in H2O) at 0 °C. The mixture was vortexed for 1 s and maintained
at 0 °C for 2 h, after which the mixture was analyzed by LCMS.
Analysis showed that the double conjugate 5 had been formed (mass
) 14 573) in near quantitative conversion.
Formation of the Protein-Sugar Bioconjugate 6. The solution
of 4 was treated with  -1-thioglucose, sodium salt (5 µL, 2.82 mM
solution in H2O) at 0 °C. The mixture was vortexed for1sa n d
maintained at 0 °C for 2 h, after which the mixture was analyzed
by LCMS. Analysis showed that the double conjugate 6 (mass )
14461) was formed in near quantitative conversion.
Mercaptoethanol- or Glutathione-Mediated Cleavage of 5
To Regenerate Protein 1. The solution of 5 was treated with
2-mercaptoethanol or glutathione (5 µL, 282 mM solution in H2O)
at 0 °C. The mixture was vortexed for 1 s and maintained at 0 °C
for 4 h, after which the mixture was analyzed by LCMS. Analysis
showed that the Grb2-SH2 (L111C) 1 (mass ) 14 170) was formed
in quantitative conversion.
Mercaptoethanol- or Glutathione-Mediated Cleavage of 6
To Regenerate Protein 1. The solution of 6 was treated with
2-mercaptoethanol or glutathione (5 µL, 282 mM solution in H2O)
at 0 °C. The mixture was vortexed for 1 s and maintained at 0 °C
for 4 h, after which the mixture was analyzed by LCMS. Analysis
showed that the Grb2-SH2 (L111C) 1 (mass ) 14170) was formed
in quantitative conversion.
Modiﬁcation of Grb2-SH2 (L111C) 1 with NEM. To a solution
of Grb2-SH2 (L111C) (100 µL, [protein] 2.0 mg/mL, 100 mM
sodium phosphate, 150 mM NaCl, pH 8.0) at 0 °C was added
N-ethylmaleimide (5 µL, 2.82 mM solution in DMF). The mixture
was vortexed for 1 s and then maintained at 0 °C for 1 h. Analysis
using LCMS showed that the desired conjugate 7 had been formed
in quantitative conversion (mass 14 295). The solution of 7 was
treated with either 2-mercaptoethanol (5 µL, 282 mM solution in
H2O) or TCEP·HCl (5 µL, 282 mM solution in H2O), vortexed
for 1 s, and maintained at 37 °C for 4 h, after which the mixtures
were analyzed by LCMS, showing no reaction had occurred in either
case.
Reaction Proﬁle Experiments of N-Methylbromomaleim-
ide, Dibromomaleimide, N-Ethylmaleimide, and Iodoacet-
amide with Grb2-SH2 (L111C) 1. To a solution of Grb2-SH2
(L111C) (100 µL, [protein] 2.0 mg/mL, 100 mM sodium phosphate,
150 mM NaCl, pH 8.0) at 0 °C was added the relevant electrophile
(5 µL, 2.82 mM solution in DMF). The mixture was vortexed for
1 s and then maintained at 0 °C. The reaction was sampled at regular
time intervals and reaction progress monitored by MS. Percentage
reaction completion was determined using total ion count (TIC)
via the formula TIC adduct/(TIC adduct + TIC unreacted Grb2)
× 100. Iodoacetamide resulted in <5% reaction after 30 min, and
thus no time points are shown for this reaction. Reactions were
performed in triplicate, and percentage reaction completion was
plotted as the mean value. Errors were determined and are reported
both as standard deviations and standard errors in the Supporting
Information.
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sugar-protein bioconjugate 6 (made as described above) was
subjected to a buffer swap (Micro Bio-Spin 6 Chromatography
Column, Bio-Rad). To a solution of 6 (95 µL, [adduct] 0.2 mg/
mL, 20 mM HEPES, 100 mM KCl, 1 mM MgCl2, 1 mM EDTA,
pH 7.4) was added glutathione (5 µL, 20 mM solution in 20 mM
HEPES, 100 mM KCl, 1 mM MgCl2, 1 mM EDTA, pH 7.4). The
mixture was vortexed for 1 s then maintained at 37 °Cf o r4h .
Analysis showed that Grb2-SH2 (L111C) 1 was formed (mass )
14 170) in quantitative conversion.
Bridging of Somatostatin with Dibromomaleimide. Lyophilized
somatostatin (mass ) 1638) was solubilized in buffer (50 mM
sodium phosphate, pH 6.2, 40% MeCN, 2.5% DMF) to yield a
concentration of 152.6 µM (0.25 mg/mL) and reduced with 1.1
equiv of TCEP for1ha t2 0°C. Completeness of the reduction
was conﬁrmed by LCMS (mass ) 1640); 1.1 equiv of dibromo-
maleimide was added and the reaction maintained at 20 °Cf o r1h .
Quantitative insertion of the maleimide into the disulﬁde bond to
give conjugate 8 was conﬁrmed by LCMS (mass ) 1734).
Mercaptoethanol-Mediated Cleavage of 8 To Regenerate
Reduced Somatostatin 9. The solution of 8 was treated with
2-mercaptoethanol (100 equiv) and the reaction maintained at 4
°C for 1 h. Analysis by LCMS showed complete cleavage of the
conjugate, yielding reduced somatostatin 9 (mass ) 1640).
Bridging of Somatostatin with N-Fluoresceindibromomale-
imide. Lyophilized somatostatin (mass ) 1638) was solubilized in
buffer (50 mM sodium phosphate, pH 6.2, 40% MeCN, 2.5% DMF)
to yield a concentration of 152.6 µM (0.25 mg/mL) and reduced
with 1.1 equiv of TCEP for1ha t2 0°C. Completeness of the
reduction was conﬁrmed by LCMS (mass ) 1640); 1.1 equiv of
N-ﬂuoresceindibromomaleimide was added and the reaction main-
tained at 20 °C for 10 min. Quantitative insertion of the maleimide
into the disulﬁde bond to give conjugate 11 was conﬁrmed by
LCMS (mass ) 2066) [M+1 peak of product above spectrometer
threshold, M+2 (m/z ) 1033) and M+3 (m/z ) 689) clearly
visualized].
Mercaptoethanol-Mediated Cleavage of 11 To Regenerate
Reduced Somatostatin 9. The solution of 11 was treated with
2-mercaptoethanol (100 equiv) and the reaction maintained at 4
°C for 1 h. Analysis by LCMS showed complete cleavage of the
conjugate yielding reduced somatostatin 9 (mass ) 1640).
2-tert-Butoxycarbonylamino-3-[4-(2-tert-butoxycarbonylamino-
2-methoxycarbonyl-ethylsulfanyl)-2,5-dioxopyrrolidin-3-ylsulfanyl]-
propionic Acid Methyl Ester (Inseparable Mixture of Diastereo-
mers). N-Boc-Cys-OMe (660 mg, 2.81 mmol) in N,N-dimethyl-
formamide (DMF) (0.25 mL) was added to a stirred solution of
bromomaleimide (50 mg, 0.281 mmol) in aqueous buffer (100 mM
sodium phosphate, 150 mM NaCl, pH 8.0):DMF 95:5 (9.25 mL),
and the reaction was stirred at 25 °C for 5 min. The aqueous reaction
mixture was extracted with ethyl acetate (3 × 25 mL). The
combined organic layers were washed with saturated lithium
chloride solution (aq) (5 × 25 mL), water (25 mL), and brine (25
mL); dried (MgSO4); and ﬁltered, and the solvent was removed in
vacuo. Puriﬁcation by column chromatography (gradient elution
10-40% ethyl acetate in petroleum ether 40-60 °C) gave the
product as a yellow waxy oil (150 mg, 0.265 mmol, 94% yield),
an inseparable 1:1 mix of two symmetrical diastereomers: 1H NMR
(400 MHz, CDCl3) δ 8.62 (s, 1H, NH from one diastereomer), 8.66
(s, 1H, NH from one diastereomer), 5.62 (d, 2H, J ) 8.4, 2 × NH
from one diastereomer), 5.51 (d, 2H, J ) 8.0, 2 × NH from one
diastereomer), 4.72-4.58 (m, 4 × R-CH from both diastereomers),
3.80 (s, 6H, 2 × CH3 from one diastereomer), 3.79 (s, 6H, 2 ×
CH3 from one diastereomer), 3.68 (s, 2H, 2 × succinimide CH
from one diastereomer), 3.64 (s, 2H, 2 × succinimide CH from
one diastereomer), 3.46 (dd, 2H, J ) 4.8 and 12.0 Hz, 2 × CHH
from one diastereomer), 3.37 (dd, 2H. J ) 6.0 and 14.4, 2 × CHH
from one diastereomer), 3.21 (dd, 2H, J ) 4.8 and 14.0 Hz, 2 ×
CHH from one diastereomer), 3.11 (dd, 2H, J ) 6.4 and 14.0 Hz,
2 × CHH from one diastereomer), 1.463 (s, 18H, 6 × CH3 from
one diastereomer), 1.460 (s, 18H, 6 × CH3 from one diastereomer);
13C NMR (125 MHz, CDCl3) (three signals missing due to overlap
of diastereomers) δ 174.32 (CdO), 171.25 (CdO), 155.33 (CdO),
80.61 (C), 80.58 (C), 53.51 (CH), 53.18 (CH), 52.91 (CH3), 52.90
(CH3), 48.45 (CH), 47.89 (CH), 34.66 (CH2), 34.59 (CH2), 28.37
(CH3), 28.36 (CH3); IR (thin ﬁlm, neat) 3348, 2978, 1719 cm-1;
LRMS (EI) 566 (20), 564 (100 [M - H]-); HRMS (EI) calcd for
C22H34N3O10S2 [M - H]- 564.1669; observed 564.1686.
N-Fluoresceindibromomaleimide 10. Dibromomaleic anhy-
dride
17 (77.0 mg, 0.30 mmol) was added in one portion to a solution
of ﬂuoresceinamine isomer 1 (105 mg, 0.30 mmol) in AcOH (10
mL) and the reaction mixture was stirred for6ha troom
temperature. The solid was then ﬁltered off, washed with EtOAc,
and resuspended in AcOH (10 mL). The reaction mixture was then
heated to reﬂux for 3 h. Upon cooling to room temperature, toluene
(10 mL) was added and the solvent removed in vacuo. This
procedure was repeated twice more to azeotropically remove the
AcOH, affording 10 as an orange solid (148 mg, 0.25 mmol, 84%
yield): 1H NMR (400 MHz, CD3OD) δ 8.07 (d, J ) 1.5 Hz, 1H,
CH), 7.81 (dd, J ) 1.5, 2.0 Hz, 1H, CH), 7.34 (d, J ) 8.5 Hz, 1H,
CH), 6.71 (d, J ) 2.5 Hz, 2H, CH), 6.66 (d, J ) 8.5 Hz, 2H, CH),
6.58 (dd, J ) 1.5, 2.5 Hz, 2H, CH); 13C NMR (150 MHz, CD3OD)
δ 170.23 (C), 164.34 (C), 161.63 (C), 154.18 (C), 152.93 (C),
134.59 (C), 134.19 (CH), 131.01 (C), 130.35 (CH), 129.25 (C),
126.25 (CH), 123.63 (CH), 113.84 (CH), 111.02 (C), 103.55 (CH);
IR (MeOH) 3063, 2924, 1725, 1588 cm-1; HRMS (ES+) calcd
for C24H12NO7Br2 [M+H]+ 583.8980, observed 583.8964; mp >220
°C (dec).
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